Related Experiment Video

Updated: Jun 9, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor

Snigdha Praharaj1, Douglas Overbey, Michael F Giblin

  • 1Harry S Truman Memorial Veterans' Administration Hospital, Research Service, A004, Columbia, MO 6520, USA.

Future Oncology (London, England)
|August 31, 2010
PubMed

Insights

New radiopharmaceuticals target specific cancer markers like guanylate cyclase C for colorectal cancer and urokinase plasminogen activator receptor for broader cancer imaging and treatment.

Area of Science:

  • Oncology
  • Radiopharmaceutical Development
  • Molecular Imaging

Background:

  • Radiopharmaceuticals targeting somatostatin receptors are clinically successful for cancer imaging and treatment.
  • This success drives research into other radiolabeled peptides for molecular imaging and peptide-receptor radiotherapy.
  • Well-studied peptide vectors include cholecystokinin, neurotensin, bombesin, and RGD peptides.

Purpose of the Study:

  • To review the current status of novel molecular imaging targets for cancer.
  • Focus on guanylate cyclase C (GC-C) as a specific marker for colorectal cancer.
  • Focus on urokinase plasminogen activator receptor (uPAR) as a target in diverse cancer types.

Main Methods:

  • Review of preclinical and clinical research on radiolabeled peptides.
  • Analysis of guanylate cyclase C as a target for colorectal cancer.
  • Analysis of urokinase plasminogen activator receptor as a target for various cancers.

Main Results:

  • Guanylate cyclase C is a validated target for colorectal cancer imaging and therapy.
  • Urokinase plasminogen activator receptor shows promise as a target in multiple cancer types.
  • Emerging radiopharmaceuticals are expanding molecular imaging and therapy options.

Conclusions:

  • Guanylate cyclase C and urokinase plasminogen activator receptor represent promising new targets in nuclear oncology.
  • Further development of receptor-specific radiopharmaceuticals will enhance cancer detection and treatment.
  • Radiolabeled peptides are crucial for advancing personalized cancer medicine.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...